Vericel (NASDAQ:VCEL) Insider Sean Flynn Sells 15,000 Shares of Stock

Vericel Corporation (NASDAQ:VCEL) insider Sean Flynn sold 15,000 shares of Vericel stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $40.21, for a total value of $603,150.00. Following the transaction, the insider owned 1,647 shares in the company, valued at $66,225.87. This represents a 90.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Vericel Trading Up 0.9%

NASDAQ:VCEL opened at $40.47 on Tuesday. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of 96.36 and a beta of 1.12. Vericel Corporation has a 1-year low of $28.95 and a 1-year high of $43.57. The business’s fifty day moving average price is $35.45 and its 200 day moving average price is $35.64.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Vericel had a return on equity of 6.41% and a net margin of 7.35%.The firm had revenue of $68.43 million during the quarter, compared to analyst estimates of $63.68 million. During the same period last year, the company posted ($0.23) EPS. The business’s quarterly revenue was up 30.1% compared to the same quarter last year. Equities analysts forecast that Vericel Corporation will post 0.49 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on VCEL. Leerink Partners reaffirmed an “outperform” rating and set a $46.00 price objective on shares of Vericel in a research report on Tuesday, March 10th. Wall Street Zen downgraded shares of Vericel from a “buy” rating to a “hold” rating in a research report on Sunday, June 14th. Truist Financial decreased their target price on shares of Vericel from $48.00 to $42.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. HC Wainwright restated a “buy” rating and set a $64.00 price target on shares of Vericel in a report on Friday, May 8th. Finally, Weiss Ratings raised shares of Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 16th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $52.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Glenmede Trust Co. NA lifted its position in Vericel by 18.4% during the 1st quarter. Glenmede Trust Co. NA now owns 15,097 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 2,348 shares during the last quarter. Bank of America Corp DE grew its position in shares of Vericel by 19.7% in the first quarter. Bank of America Corp DE now owns 1,098,771 shares of the biotechnology company’s stock valued at $35,347,000 after purchasing an additional 180,761 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Vericel by 26.3% in the first quarter. California State Teachers Retirement System now owns 61,233 shares of the biotechnology company’s stock valued at $1,970,000 after purchasing an additional 12,767 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in shares of Vericel by 1.6% in the first quarter. Rice Hall James & Associates LLC now owns 132,063 shares of the biotechnology company’s stock worth $4,248,000 after purchasing an additional 2,094 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Vericel in the first quarter worth about $405,000.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.